Finance News – U.S.
What is your interest today?
Tariffs
Ceo
Investors
Stock
Earnings
Shares
Stocks
China
Markets
Nasdaq
Eqs
Investment
Trade
Wall Street
Nvidia
Cet
Revenue
Tesla
Stock Market
Economy
Class Action
Securities
Sales
Bitcoin
Trade War
Prices
Inflation
Company
Us
Apple
Crypto
Warren Buffett
Sp 500
Guidance
Berkshire Hathaway
Amazon
Shareholders
Federal Reserve
Ipo
Companies
Walmart
Federal Securities Laws
Pvr
Profit
Trading
Investor
Interest Rates
Recession
Forecast
Monetary Policy
Class Action Lawsuit
Article 40
Vote
Price Target
Ride Hailing
Rate Hedged
Videogame Business
Malware
Memecoin
Nuclear Power Reactors
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Find stories in U.S. outlets…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Business Insider Markets • May 29, 2025
Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Shareholders of Class Action Lawsuit and June...
Shareholders of Zenas BioPharma, Inc. may have an opportunity to recover investment losses through a federal securities lawsuit, with important claim submission deadlines approachi...
Read Full Article →
Business Insider Markets • May 28, 2025
Class Action Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025...
Investors in Zenas BioPharma, Inc. who experienced financial losses may have an opportunity to seek compensation if they take action before the approaching mid-June 2025 deadline.
Read Full Article →
Business Insider Markets • May 27, 2025
ROSEN, SKILLED INVESTOR COUNESL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before...
Investors in Zenas BioPharma, Inc. may have the opportunity to participate in a securities class action seeking potential compensation related to alleged financial misconduct befor...
Read Full Article →